This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ito, K. Articles by Garrett, C. T. Search for Related Content PubMed PubMed Citation Articles by Ito, K. Articles by Garrett, C. T.

Prognostic Significance of p53 Overexpression in Endometrial Cancer¹

Department of Obstetrics and Gynecology [K. I., K. W., S. S., A. Y.] and Pathology [H. S.], Tohoku University School of Medicine, Sendai, Japan, and Department of Pathology, George Washington University Medical Center, Washington, DC 20052 [S. N., S. G. S., C. T. G.]

Abnormalities of p53, a tumor suppressor gene, have been considered to play an important role in tumorigenesis. Clinically, overexpression of p53 has been reported to correlate with poor prognosis in several types of tumors. In this study, we examined 221 cases of endometrioid endometrial carcinoma for overexpression of p53 using immunohistochemistry in patients with a median follow-up of 41 months. Immunohistochemical analysis was performed with monoclonal antibody pAbl801. Overexpression of p53 was detected in 47 of 221 cases (21.3%). There was a statistically significant correlation between p53 overexpression and poor prognosis (P < .0001). In the early stages of cancer (stages 1 and 2), p53 was overexpressed in 11 of 22 patients (50%) who died or had a recurrence during follow-up. In contrast, overexpression was detected in only 14.7% of the 156 disease-free patients during the same period (P < .0001). In advanced stages (stages 3 and 4), tumors from patients with recurrent disease had a higher frequency of overexpression (41.2%; 7 of 17) than those of disease-free patients (23.1%; 6 of 26). However, the difference between these frequencies was not statistically significant. In multivariate analysis using the Cox proportional hazard model, p53 overexpression was an independent risk factor when compared with clinical stage, nuclear grade, and patient age. Our results indicate that p53 immunohistochemical evaluation of the most common form of endometrial cancer may be useful in identifying cases of aggressive carcinoma, especially in the early stages.

¹ Supported in part by the National Cancer Institute Grant RO1 CA 47994 and a gift from the Elaine Snyder Research Foundation.

² To whom requests for reprints should be addressed, at Department of Pathology, Medical College of Virginia, P.O. Box 980662, Richmond, VA 23298-0662.

Received 3/18/94. Accepted 7/ 6/94.

This article has been cited by other articles:

				O. Graesslin, S. Chantot-Bastaraud, M. Lorenzato, P. Birembaut, C. Quereux, and E. Darai Fluorescence in situ Hybridization and Immunohistochemical Analysis of p53 Expression in Endometrial Cancer: Prognostic Value and Relation to Ploidy Ann. Surg. Oncol., February 1, 2008; 15(2): 484 - 492. [Abstract] [Full Text] [PDF]

				K. Ito, T. Suzuki, J.-i. Akahira, M. Sakuma, S. Saitou, S. Okamoto, H. Niikura, K. Okamura, N. Yaegashi, H. Sasano, et al. 14-3-3{sigma} in Endometrial Cancer-A Possible Prognostic Marker in Early-Stage Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7384 - 7391. [Abstract] [Full Text] [PDF]

				S. E. Ferguson, A. B. Olshen, A. Viale, R. R. Barakat, and J. Boyd Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene Expression Profiles Clin. Cancer Res., March 15, 2005; 11(6): 2252 - 2257. [Abstract] [Full Text] [PDF]

				G. L. Maxwell, J. I. Risinger, K. A. Hayes, A. A. Alvarez, R. K. Dodge, J. C. Barrett, and A. Berchuck Racial Disparity in the Frequency of PTEN Mutations, but not Microsatellite Instability, in Advanced Endometrial Cancers Clin. Cancer Res., August 1, 2000; 6(8): 2999 - 3005. [Abstract] [Full Text]

				S. S. E. Fernando, X. Wu, and L. S. Perera p53 Overexpression and Steroid Hormone Receptor Status in Endometrial Carcinoma International Journal of Surgical Pathology, July 1, 2000; 8(3): 213 - 222. [Abstract] [PDF]

				H. B. Salvesen, S. Das, and L. A. Akslen Loss of Nuclear p16 Protein Expression Is Not Associated with Promoter Methylation but Defines a Subgroup of Aggressive Endometrial Carcinomas with Poor Prognosis Clin. Cancer Res., January 1, 2000; 6(1): 153 - 159. [Abstract] [Full Text]

				H. B. Salvesen, O. E. Iversen, and L. A. Akslen Prognostic Significance of Angiogenesis and Ki-67, p53, and p21 Expression: A Population-Based Endometrial Carcinoma Study J. Clin. Oncol., May 1, 1999; 17(5): 1382 - 1382. [Abstract] [Full Text] [PDF]

				H. J. Ahn, K. W. Kwon, Y. J. Choi, and N. H. Cho Expression of Cyclin E and Cyclin-Dependent Kinase Inhibitor, p27KIP1 in Uterine Endometrial Carcinoma: Relationship with p53 Status International Journal of Surgical Pathology, October 1, 1998; 6(4): 205 - 212. [Abstract] [PDF]

				M. McHugh, S. Bose, and J. P. Palazzo p53 Expression in Endocervical and Endometrial Adenocarcinomas: An Immunohistochemical Study With Clinical Correlation International Journal of Surgical Pathology, April 1, 1995; 2(4): 269 - 273. [Abstract] [PDF]